









Markets
/
Stocks
/
nasdaq-eypt
/

EyePoint Pharmaceuticals Inc

EYPT

13.760USD

+0.120+0.88%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

947.92MMarket Cap

LossP/E TTM



EyePoint Pharmaceuticals Inc

13.760

+0.120+0.88%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

51 / 175

Overall Ranking

156 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

35.182

Target Price

+158.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 27.99.

Undervalued

The company’s latest PE is -5.07, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 78.45M shares, decreasing 11.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.80M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.19, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 5.33M, representing a year-over-year decrease of 43.73%, while its net profit experienced a year-over-year decrease of 92.78%.

Score

Industry at a Glance

Previous score

6.19

Change



Financials

7.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.65

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -5.07, which is -48.39% below the recent high of -2.62 and 7.29% above the recent low of -4.70.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.62, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for EyePoint Pharmaceuticals Inc is 31.00, with a high of 68.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

35.182

Target Price

+157.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

EyePoint Pharmaceuticals Inc

EYPT

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 9.16, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 15.06 and the support level at 11.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.044

Buy

RSI(14)

66.971

Neutral

STOCH(KDJ)(9,3,3)

63.695

Neutral

ATR(14)

0.765

High Vlolatility

CCI(14)

62.947

Neutral

Williams %R

20.886

Buy

TRIX(12,20)

1.005

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

13.552

Buy

MA10

13.649

Buy

MA20

12.708

Buy

MA50

11.360

Buy

MA100

9.573

Buy

MA200

8.244

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 113.85%, representing a quarter-over-quarter increase of 2.66%. The largest institutional shareholder is The Vanguard, holding a total of 3.80M shares, representing 5.52% of shares outstanding, with 0.81% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

8.32M

Suvretta Capital Management, LLC

6.80M

+0.31%

Adage Capital Management, L.P.

6.20M

+7.83%

BlackRock Institutional Trust Company, N.A.

4.95M

+4.36%

Franklin Advisers, Inc.

4.12M

+0.23%

The Vanguard Group, Inc.

Star Investors

3.82M

+0.82%

Federated Hermes Global Investment Management Corp.

3.71M

+0.07%

TCG Crossover Management, LLC

3.57M

Citadel Advisors LLC

2.29M

-7.33%

Geode Capital Management, L.L.C.

1.59M

+3.52%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.12, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.